PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 226
- Registration Number
- NCT01712061
- Locations
- π¨π¦
Co-Medica Research Network Inc., Courtice, Ontario, Canada
πͺπΈHospital Universitario Vall d'Hebron, Barcelona, Spain
πΊπΈClinical Trial Network, Houston, Texas, United States
Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01710046
- Locations
- πΊπΈ
Olympian Clinical Research, Tampa, Florida, United States
πΊπΈDermatology Research Associates, Los Angeles, California, United States
πΊπΈCenter for Clinical Studies, Houston, Texas, United States
Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01710020
- Locations
- πΊπΈ
Pfizer Investigational Site, Minneapolis, Minnesota, United States
A Study Of CP-690,550 In Stable Kidney Transplant Patients
- Conditions
- Kidney Transplant
- Interventions
- Drug: CP-690,550 15 mg BIDDrug: CP-690,550 5 mg BIDDrug: PlaceboDrug: CP-690,550 30 mg BID
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2012-12-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT01710033
- Locations
Pfizer Investigational Site
A Study To Test The Safety, Amount And Effects Of PF-06282999 In Healthy Overweight Adults And A Study To Test The Effects Of PF-06282999 On The Amount Of The Approved Drug, Midazolam, In Healthy Adults
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 69
- Registration Number
- NCT01707082
- Locations
- π§πͺ
Pfizer Investigational Site, Brussels, Belgium
A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01706796
- Locations
- πΈπ¬
Pfizer Investigational Site, Singapore, Singapore
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
- Conditions
- Clostridium Difficile Associated Disease
- Interventions
- Biological: C. difficile vaccine +adjuvantBiological: C. difficile vaccine
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 192
- Registration Number
- NCT01706367
- Locations
- πΊπΈ
Pfizer Investigational Site, Cary, North Carolina, United States
Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT01702506
- Locations
- π§πͺ
Pfizer Investigational Site, Bruxelles, Belgium
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 780
- Registration Number
- NCT01692899
A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China
- Conditions
- Pneumococcal Infection
- Interventions
- Biological: 13-valent Pnumococcal Conjugate vaccineBiological: 7-valent Pneumococcal Conjugate Vaccine
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1674
- Registration Number
- NCT01692886
- Locations
- π¨π³
Jiangsu Province Lianshui County Center for Disease prevention and Control, Lianshui County, Jiangsu, China
π¨π³Jiangsu Province Huaiyin District Center for Disease prevention and Control, Huaian City, Jiangsu, China
π¨π³Jiangsu Province Guanyun County Center for Disease prevention and Control, Guanyun County,, Jiangsu, China